The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

68 Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177 Lu-PSMA617 in 8 patients with PSA decline ? 98 percent in a prospective phase II study. Any disease ...

Its targeted nature makes it a valuable option for managing advanced prostate cancer. Lutetium-177 has played an important role in treating advanced prostate cancer. It attaches to specific ...

Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand ®) to support AtomVie's CDMO activities for radiopharmaceutical manufacturing.

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline ... third parties nor do we endorse or guarantee their products. We make no representation or ...

Through this partnership, AtomVie secures reliable access to Theralugand ®, which will enable further development of Lu-177 based radiopharmaceuticals in their facility. The flexibility of the ...

EQS-News: Eckert & Ziegler SE / Key word(s): Incoming Orders/Agreement Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply 20.03.2025 / 14:00 CET/CEST ...